Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (351-360 of 688) with videos related to

Pageof 69
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 24, 2021
Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trialPieter Martens, João Pedro Ferreira, John Vincent, et al.
European Journal of Heart Failure|April 21, 2025
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weightJawad H Butt, Scott D Solomon, Muthiah Vaduganathan, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 4, 2019
Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rateKen Lee Chin, Timothy Collier, Stuart Pocock, et al.
JAMA|July 15, 2015
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical TrialGeorge L Bakris, Bertram Pitt, Matthew R Weir, et al.
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Circulation|November 17, 2020
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 DiabetesGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.
The New England Journal of Medicine|December 2, 2020
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
Circulation|November 15, 2021
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD TrialGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.
JACC. Heart Failure|November 3, 2022
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and DiabetesGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.
Journal of the American College of Cardiology|June 6, 2020
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art ReviewJoão Pedro Ferreira, Javed Butler, Patrick Rossignol, et al.
Pageof 69

Showing results (351-360 of 688) with videos related to

Sort By:
Pageof 69
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 24, 2021
Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trialPieter Martens, João Pedro Ferreira, John Vincent, et al.
European Journal of Heart Failure|April 21, 2025
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weightJawad H Butt, Scott D Solomon, Muthiah Vaduganathan, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 4, 2019
Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rateKen Lee Chin, Timothy Collier, Stuart Pocock, et al.
JAMA|July 15, 2015
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical TrialGeorge L Bakris, Bertram Pitt, Matthew R Weir, et al.
The New England Journal of Medicine|November 22, 2014
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitorsMatthew R Weir, George L Bakris, David A Bushinsky, et al.
Circulation|November 17, 2020
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 DiabetesGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.
The New England Journal of Medicine|December 2, 2020
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
Circulation|November 15, 2021
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD TrialGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.
JACC. Heart Failure|November 3, 2022
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and DiabetesGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.
Journal of the American College of Cardiology|June 6, 2020
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art ReviewJoão Pedro Ferreira, Javed Butler, Patrick Rossignol, et al.
Pageof 69